Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer

16. Mai 2012 aktualisiert von: UNC Lineberger Comprehensive Cancer Center

A Pilot Study of the Biologic Efficacy and Safety of the Addition of Celecoxib to a Program of Induction Chemotherapy and Neo-Adjuvant Chemo-Radiotherapy for the Treatment of Esophageal Cancer

RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy and radiation therapy together with celecoxib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving irinotecan and cisplatin together with radiation therapy with or without celecoxib works in treating patients with stage II, stage III, or stage IV esophageal cancer.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

OBJECTIVES:

Primary

  • To measure the rates of cellular apoptosis and proliferation at baseline and during chemoradiotherapy with and without celecoxib using biopsy samples from patients with stage II, III, or IV esophageal cancer.
  • To determine if an acceptable rate of pathologic complete remission can be achieved in a subset of patients with potentially resectable esophageal cancer.

Secondary

  • To assess the safety of the addition of daily celecoxib to chemoradiotherapy.
  • To estimate the median overall survival in a subset of patients with resectable disease.
  • To quantitate expression of cyclooxygenase (COX)-2 and formation of prostaglandin E2 (PGE2) in patients with esophageal cancer.
  • To assess the ability of celecoxib to decrease formation of PGE2 in tumor tissue by measuring pre- and post-treatment tumor concentrations of PGE2.
  • To quantitate downstream effects of inhibition of COX-2 function in the setting of treatment with chemotherapy.
  • To measure the radiographic response rate in patients with unresectable esophageal cancer.

OUTLINE: This is a multicenter study. Patients are sequentially enrolled into 1 of 2 treatment groups.

  • Group 1: Patients receive cisplatin IV over 1 hour and irinotecan hydrochloride IV over 90 minutes on days 1, 8, 22, 29, 43, 50, 64, and 71. Patients also undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 43.
  • Group 2: Patients receive chemoradiotherapy as in group 1. Patients also receive oral celecoxib twice daily beginning 3 days before the initiation of chemotherapy and continuing until the completion of chemoradiotherapy.

In both groups, patients with potentially resectable disease undergo surgery no more than 12 weeks after completion of chemoradiotherapy.

Endoscopic tumor biopsy specimens are collected at baseline and on day 3 of radiotherapy. Samples are analyzed for cyclooxygenase (COX)-2 gene and protein expression; PGE2 secretion; apoptotic activity; caspase-3 activation; cytochrome c translocation; VEGF mRNA quantitation; and cellular proliferation. Laboratory techniques used include RT-PCR, IHC, enzyme immunoassay, TUNEL assay, colorimetric assay, and northern blotting.

After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 34 patients (8-10 in group 1 and 24 in group 2) will be accrued for this study.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

14

Phase

  • Phase 2

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

DISEASE CHARACTERISTICS:

  • Biopsy proven squamous cell carcinoma or adenocarcinoma of the esophagus

    • Lesions including the gastroesophageal junction allowed provided the tumor involves less than 2 cm of gastric cardia

  • Meets 1 of the following criteria:

    • Clinical stage II, III, or IV disease AND planning to receive chemoradiotherapy either for preoperative or palliative indications (group 1)

      • Suitable candidate for bimodality (palliative intent) or trimodality (curative intent) therapy

    • Clinical stage II or III disease AND candidate to receive chemoradiotherapy for preoperative indication followed by planned esophagectomy or esophagogastrectomy (group 2)

      • Suitable candidate for trimodality (curative intent) therapy
  • No tracheoesophageal fistula on bronchoscopy

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Life expectancy > 3 months (group 1)
  • Not pregnant
  • Adequate nutrition
  • WBC ≥ 4,000/μL
  • ANC ≥ 1,500/μL
  • Platelet count ≥ 100,000/μL
  • Serum creatinine ≤ 1.5 mg/dL
  • Bilirubin ≤ 1.5 mg/dL

  • No other prior or concurrent malignancy other than curatively treated carcinoma in situ of the cervix; localized prostate cancer that was previously treated with local therapy more than 2 years ago with a PSA of less than 4 ng/mL; basal cell carcinoma of the skin; or superficial transitional cell carcinoma of the bladder

    • Patients who have had a prior malignancy are eligible if they have been free of disease for ≥ 5 years
  • No serious medical or psychiatric illnesses that would preclude giving informed consent or otherwise limit survival to less than 2 years
  • No history of known NSAID-induced gastrointestinal bleeding
  • No current peptic ulcer disease
  • No active coronary artery disease
  • No myocardial infarction or cerebrovascular accident within the past 3 months
  • No history of refractory congestive heart failure or cardiomyopathy

PRIOR CONCURRENT THERAPY:

  • More than 1 week since prior major surgery (group 1)
  • More than 2 weeks since prior major surgery (group 2)
  • No prior chemotherapy or radiotherapy

  • More than 30 days since prior cyclooxygenase-2 inhibitors (selective or non-selective), including, but not limited to, any of the following:

    • Acetylsalicylic acid (aspirin)
    • Piroxicam
    • Diclofenac
    • Meloxicam
    • Indomethacin
    • Fenoprofen
    • Sulindac
    • Flurbiprofen
    • Tolmetin
    • Ibuprofen
    • Celecoxib
    • Ketoprofen
    • Rofecoxib
    • Ketoprofen ER
    • Valdecoxib
    • Naproxen
    • Meclofenamate
    • Oxaprozin
    • Mefenamic acid
    • Etodolac
    • Nabumetone
    • Ketorolac
  • No concurrent seizure medications
  • No concurrent amifostine or other such agents

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Cohort 1
Induction chemotherapy and chemoradiation without celecoxib
Arzneimittel: CPT- 11
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Andere Namen:
  • Irinotecan
Arzneimittel: Cisplatin
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Andere Namen:
  • Cis-diammine-dichloro-platinum
Strahlung: Radiation
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Verfahren: Surgery
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
Experimental: Cohort 2
Induction chemotherapy and chemoradiation with celecoxib
Arzneimittel: CPT- 11
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Andere Namen:
  • Irinotecan
Arzneimittel: Cisplatin
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Andere Namen:
  • Cis-diammine-dichloro-platinum
Strahlung: Radiation
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Verfahren: Surgery
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
Arzneimittel: Celecoxib
400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Rates of cellular apoptosis and proliferation
Zeitfenster: 5 weeks
Measure the rates of cellular apoptotis and proliferation in esophageal cancers from biopsy samples pre-study and during chemoradiation with and without celecoxib therapy
5 weeks
Rate of pathologic complete remission in patients with resectable disease
Zeitfenster: 4 years
To determine if an acceptable rate of pathologic complete remissions can be achieved in a cohort of patients with potentially resectable esophageal carcinoma
4 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of subjects experiencing adverse events
Zeitfenster: 30 days post radiation
Adverse events/toxicity will graded per the CTCAE criteria
30 days post radiation
Median overall survival of patients with resectable disease
Zeitfenster: 4 years
Follow up for survival will occur at 3 month intervals during the first two years, then every 6 months during years 3 and 4.
4 years
Formation of prostaglandin E2 (PGE2) in tumor tissue
Zeitfenster: 12 weeks
The ability of celecoxib to decrease formation of prostaglandin E2 (PGE2) in tumor tissue will be analyzed using a Wilcoxon signed rank test on the difference (log scale) of the pre- and post-treatment tumor concentrations of PGE2
12 weeks
Downstream effects of inhibition of cyclooxygenase 2 function
Zeitfenster: 12 weeks
A difference in location of the mRNA expression of the two cohorts will be tested for using the Wilcoxon rank sum test. A difference in the immunohistochemistry staining of the two cohorts will be tested for using polytomous logistic regression
12 weeks
Response Rate
Zeitfenster: 4 years
Radiographic repsonse will be measured using RECIST critera in patients with unresectable esophageal cancer.
4 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

UNC Lineberger Comprehensive Cancer Center

Mitarbeiter

National Cancer Institute (NCI)

Ermittler

  • Hauptermittler: Bert H. O'Neil, MD, UNC Lineberger Comprehensive Cancer Center

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. März 2005

Primärer Abschluss (Tatsächlich)

1. November 2006

Studienabschluss (Tatsächlich)

1. September 2010

Studienanmeldedaten

Zuerst eingereicht

21. August 2007

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

21. August 2007

Zuerst gepostet (Schätzen)

23. August 2007

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

18. Mai 2012

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

16. Mai 2012

Zuletzt verifiziert

1. Mai 2012

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • LCCC 0203
  • CDR0000561610 (Andere Kennung: NCI PDQ identifier)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur CPT- 11

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Kosovo

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

3
Abonnieren